Names without a link are companies not yet registered in OpenBizGraph
§05
Network
NETWORK
Loading the relationship graph...
Drag to move · click to open
§06
History
122 EVENTS
A paper by developer Hirotsu clarifying the involvement of the Ras-MAPK pathway in nematode olfaction
Published in the English scientific journal "Nature"
Inoue Science Promotion Foundation
Developer Hirotsu received the "Inoue Research Encouragement Award"
The first clinical research paper by developer Hirotsu on nematode olfaction detecting cancer odors
Published in the online journal "PLOS ONE"
This invention became the top news on TV Asahi's "Reporting Station"
Reported by many other media, causing a great impact in various fields
Aiming to commercialize the nematode cancer test "N-NOSE"
Established HIROTSU BioScience Inc. (Headquarters: Akasaka, Minato-ku, Tokyo)
Institute of Science and Technology Policy, Ministry of Education, Culture, Sports, Science and Technology
Selected as a representative for "Nice Step Researchers 2016"
NeuroCreative Research Association (NPO)
Representative received the "Development Research Encouragement Award"
Science Promotion Foundation (Public Foundation)
Representative received the "Nakayama Prize Encouragement Award"
[Newly added joint clinical research site]
Minami-Fu Hospital
Implemented a third-party allotment of capital (first round in 2017)
Opened Central Research Institute, Fukuoka Research Institute, and Shikoku Analysis Center.
Representative delivered an invited lecture at the Brisbane Cancer Conference 2017.
Established Australian subsidiary HIROTSU BIO AUSTRALIA PTY. LTD.
Implemented a third-party allotment of additional shares to multiple companies (second round in 2017).
Ministry of Economy, Trade and Industry.
Our company was selected as a 'Regional Future Leading Company'.
[Newly added joint clinical research sites]
Shikoku Cancer Center, Ageo Central General Hospital Gastroenterology Department, Hills Garden Clinic, Ebara Welfare Hospital, Saitama Medical University International Medical Center Gastroenterology Department, Toda Central General Hospital Gastroenterology Department, Inazawa Welfare Hospital Gastroenterology Department, Ibi Welfare Hospital, Queensland University of Technology, Shin-Yamate Hospital Gastrointestinal Surgery & Respiratory Medicine, Minami-Fu Hospital & Shionogi Pharmaceutical, Osaka University Gastroenterology Department, Kurume University Cancer Integrated Treatment Center.
Moved headquarters to Minami-Aoyama, Minato-ku, Tokyo, due to business expansion.
Implemented a third-party allotment of additional shares to multiple companies (first round in 2018).
Fukuoka Prefecture.
Our company was selected for the Fukuoka Prefecture Innovative Cancer Ultra Early Diagnosis Technology Implementation Project.
Signed capital and business alliance agreements with Toppan Forms Co., Ltd., Azwan Co., Ltd., Ichinen Holdings Co., Ltd., Miraka Holdings Co., Ltd., Avex Co., Ltd., and Nippon Broadcasting Co., Ltd.
Implemented a third-party allotment of additional shares (second round in 2018).
Representative appointed as visiting associate professor at Queensland University of Technology.
Representative appointed as director of the Japan Society for Biological Diagnostics.
First feature on nematode cancer testing aired on an overseas program.
NHK World Japan 'NEWS ROOM TOKYO'.
Our company received its first in-depth coverage, broadcasting the research and development process.
TV Tokyo affiliate 'Gaia no Yoake'.
Newly added joint clinical research site
Tokushima University Hematology, Toda Central General Hospital Nephrology
Developer Hirotsu gave an invited lecture at the 60th Annual Meeting of the Japanese Society of Health Checkups
Representative's book 'Cancer Screening is a Worm's Work' released by Kōbunsō
Representative gave an invited presentation at the 16th Annual Meeting of the STS Forum Science and Technology in Society
Establishment of U.S. subsidiary HIROTSU & CO., INC.
Central Research Institute, Fukuoka Research Institute, Shikoku Analysis Center
Renamed to Kashiwa R&D Center, Fukuoka R&D Center, Matsuyama R&D Center
Opened HBS Tokyo Testing Center and HBS Matsuyama Testing Center
Representative gave an invited lecture at the 2021 World Alliance Forum in San Francisco
Newly added joint clinical research site
Kurume University Pediatrics
World's first nematode cancer test
Commercialized 'N-NOSE®', a primary cancer screening test
Numerous media reports on the commercialization of N-NOSE
Public Interest Incorporated Association Platinum Concept Network
Our company received the 'Excellent Award' at the 8th Platinum Award
Implemented third-party allotment capital increase for multiple companies (first round in 2020)
Successfully developed the N-NOSE fully automatic analysis device
Moved headquarters to Kioi-cho, Chiyoda-ku, Tokyo due to business expansion
Launched the individual service 'Go To N-NOSE' for N-NOSE.
Opened sample collection sites 'N-NOSE Station' in Tokyo and Fukuoka.
Relocated and opened the Kashiwa R&D Center as the new Shonan R&D Center.
The representative announced an invitation at the 4th International Health Screening Conference.
Conducted a third-party allotment of additional capital with multiple companies (second round in 2020).
[Newly added joint clinical research sites]
University of Tsukuba Pediatrics, Kyoto Prefectural University of Medicine Pediatrics, Seiryoku Medical Center Pediatric Cancer Center, Komagome City Hospital Gastroenterology, Gifu University Oncology, Ageo Central General Hospital (2), University of Tokyo Gastric and Esophageal Surgery, Teikyo University Dermatology, Showa University Gastroenterology.
Opened a sample collection site 'N-NOSE Station' in Osaka.
First nationwide, the Fukuoka Prefecture branch of the Local Employees Mutual Aid Association adopted 'N-NOSE'.
Signed a capital and business alliance agreement with Holipro Inc.
Opened 'N-NOSE Station Satellite' sample collection sites nationwide.
Conducted a third-party allotment of additional capital with multiple companies (first round in 2021).
Launched the new service 'N-NOSE at home' that allows testing to be completed at home across all 47 prefectures.
Conducted a third-party allotment of additional capital with multiple companies (second round in 2021).
Signed a capital and business alliance agreement with Mitsui Sumitomo Insurance Co., Ltd. (Aioi).
Opened a sample collection site 'N-NOSE Station' in Shinjuku.
Our first corporate TV commercial began airing in the Kansai region.
Announced that the world's first early pancreatic cancer test would be commercialized in 2022.
This announcement was reported by over 300 news media outlets.
Conducted a third-party allotment of additional capital with multiple companies (first round in 2022).
Signed a capital and business partnership agreement with Sojitz Corporation.
N-NOSE was certified by the "ME-BYO BRAND".
Questions about nematode cancer testing technology were included in entrance exams for national universities and private high schools.
Launched the "N-NOSE安心アフターサービス" (free) after-sales service.
Introduced a new plan "Regular Inspection Course" that allows annual N-NOSE testing at a fixed number of times.
Signed a capital and business partnership agreement with Tokyu Agency Co., Ltd.
Hokkaido's Sarine Town became the first nationwide adopter of "N-NOSE" for a health promotion project and implemented it for residents.
Representative delivered a keynote lecture at the 63rd Annual Meeting of the Japanese Society of Health Checkups.
N-NOSE user count surpassed 250,000.
First clinical research paper on N-NOSE targeting pets (dogs and cats) published by the company.
Published in "Biochemistry and Biophysics Reports."
Implemented an executive officer system.
Participated in the Global Innovators Community of the World Economic Forum.
Commercialized the first test "N-NOSE® plus pancreas."
Signed a capital and business partnership agreement with Anicom General Insurance Co., Ltd.
Launched the dog cancer test "N-NOSE® ワンちゃん" for pet owners.
Signed a memorandum of understanding with the Global Health Equity Fund established by the WHO Foundation and others for overseas expansion of "N-NOSE®."
Attended the World Economic Forum New Champion Annual Meeting 2023 (Summer Davos Conference).
Listed "N-NOSE®" on Alibaba Group's cross-border e-commerce platform "Tmall Global."
N-NOSE user count surpassed 500,000.
Representative delivered a presentation at the public symposium 'STS Forum 2023'.
Started accepting registrations for the cat cancer risk test 'N-NOSE Neko-chan'.
Participated in 'UBS Disruptive Technology CEO Summit 2023'.
Signed an official partnership agreement with Reco Blacklamas Tokyo.
Implemented a third-party allotment of capital (first round in 2023).
New director/CSO appointed.
Number of corporate adopters of 'N-NOSE' surpassed 2,000 companies.
Initiated a pilot study on unmanned sales and collection of 'N-NOSE'.
Successfully developed a new cancer-type identification test for liver cancer.
Appointed a global CFO to support overseas expansion.
Launched new corporate service 'N-NOSE for Business'.
Published a paper on the results of a large-scale clinical study of 'N-NOSE'.
Implemented a third-party allotment of capital (first round in 2024).
Selected as the 'Best Oral Abstract Presenter Award at EIOC 2024' at the Excellence in Oncology Care (EIOC) 2024 Conference.
A peer-reviewed review on data demonstrating the real-world effectiveness of N-NOSE was published in the international biomedical journal 'Biomedicines'.
Expanded the number of responsive cancer types from 15 to 23; launched 'N-NOSE® evolve'.
Re-released 'N-NOSE plus Pancreas', specialized for pancreatic cancer, following positive reception.
Suggested the effectiveness of 'N-NOSE' as a recurrence monitoring tool through a joint study with the University of Tokyo; the results were published in the international journal 'BMC Cancer'.
Implemented a third-party allotment of capital (second round in 2024).
Implemented a third-party allotment of capital.
Proved the efficacy of N-NOSE in detecting blood cancers
The original paper was published in the international scientific journal 'Hematological Oncology'
10 years since the invention of N-NOSE
§07
News
20 ARTICLES
Recovery of Email Sending and Receiving Issues Due to Microsoft Inc. Outage
Due to a system outage at Microsoft Inc., our email system (Outlook) experienced sending and receiving issues. The service was restored on November 13, 2026, and email sending and receiving are now functioning normally. We are currently reviewing and responding to inquiries received during the outage. We sincerely apologize for any inconvenience and trouble caused.
[Announcement] The first part of the official YouTube program "Radio That Changes the World" featuring DJ KOO (TRF) has been released
HIROTSU BioScience Co., Ltd. released the first part of a conversation with DJ KOO of TRF as a guest on the official YouTube program "Radio That Changes the World – The Nematode Doctor Becomes President." The release took place on November 16, 2026 at 18:00. DJ KOO also participates in a pediatric cancer treatment support project, and this conversation will be streamed in two parts: the first and second segments.
Email Sending and Receiving Issues Due to Microsoft Inc. Outage
Due to a system outage at Microsoft Inc., our email system that uses Outlook is unavailable, preventing the receipt and sending of emails or causing significant delays. For urgent matters, please contact the sales representative directly, and other inquiries will be addressed sequentially after service restoration.
Clearson Shinjuku Players Release N-NOSE Experience Video
HIROTSU Bioscience has released an interview video on its official YouTube channel and dedicated website, featuring Clearson Shinjuku players Shima Daijou, Nakayama Jintou, and Sawai Naoto sharing their experience of taking the "N-NOSE®" test at home. The players discuss the convenience of the test and how it provided peace of mind for themselves and their families.
N-NOSE tops the three key metrics in the major six-company survey
The first-line cancer screening test "N-NOSE®︎" achieved No.1 in the 2026 October market survey by the Japan Marketing Research Organization, ranking first among the major six companies in three categories: cumulative number of test takers, sales performance, and number of corporate welfare implementations. The company announced in July 2026 that it had surpassed one million cumulative samples and plans to continue promoting the test and improving its services. The survey results do not indicate the test’s effectiveness, efficacy, performance, or clinical superiority.
Interview with Representative Hirotsu Featured in MiraError
An interview article featuring Takayuki Hirotsu, CEO and Representative Director of HIROTSU BioScience Co., Ltd., was published in the executive interview media "MiraError." The piece introduces Hirotsu's career path, his passion for research and development, and the vision he aims to achieve through his business. The article was published on November 2, 2026.
HIROTSU BioScience Co., Ltd. Provides Special Sponsorship for the Pediatric Cancer Treatment Support Project "LIVE EMPOWER CHILDREN 2027"
HIROTSU BioScience Co., Ltd. announced its special sponsorship of the "LIVE EMPOWER CHILDREN 2027 Project," a charity live and special program hosted by the nonprofit Empower Children. From November 2026 to January 2027, the company will visit four hospitals in the Kansai area to bring music and dance performances to children and their families. A special program, "LEC TV 2027," is scheduled to be broadcast on February 15, 2027.
Official YouTube Program "Radio That Changes the World" – Director Toshifumi Miyako's Second Half Release
HIROTSU Bioscience Co., Ltd. has released the second half of the episode featuring Director Toshifumi Miyako on the official YouTube program "Radio That Changes the World." The second half includes a discussion on perspectives for selecting people, commonalities between team building and corporate management, and ways to encourage player growth.
Interview with CEO Hirotsu Featured in “Keido”
On October 28, 2026, an interview with Takaki Hirotsu, Representative Director and CEO of HIROTSU Bio Science, was published in “Keido,” a media outlet featuring interviews with business leaders. The article covers topics including his transition from researcher to business leader, organizational management, research and development, and his views on overseas expansion.
HIROTSU Bio Science Participates in STS Forum 2026
HIROTSU Bio Science, Inc. participated as a sponsor in STS Forum 2026, held from October 4 to 6, 2026, and was represented by Eric di Luccio, Senior Executive Officer and CTO. He shared his views on the frameworks needed to bring early cancer detection technologies into practical use in society and exchanged opinions with leaders in science, industry, and policymaking.
§08
Public records
GOV
National Tax Agency basic information4010401120144
Source: National Tax Agency Corporate Number Publication Site, basic three items
Trade name
株式会社HIROTSUバイオサイエンス
Trade name (kana)
ヒロツバイオサイエンス
Name in English
Corporation type
301
Address
〒102-0094 東京都千代田区紀尾井町4番1号
Postal code
1020094
Prefecture code
13
City code
101
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2020-10-13
Change date
2020-10-06
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
1748647
METI gBizINFO4010401120144
Source: gBizINFO (Ministry of Economy, Trade and Industry)